Offering

Burcon Closes Over-Subscribed $4.3 Million Non-Brokered Private Placement to Accelerate Commercial Plans

Retrieved on: 
Tuesday, March 12, 2024

Principal subscribers include Company directors, management, long-term shareholders, and new investors in support of Burcon's long-term vision.

Key Points: 
  • Principal subscribers include Company directors, management, long-term shareholders, and new investors in support of Burcon's long-term vision.
  • "We are excited to announce the successful completion of our private placement and combined with non-dilutive capital sources, fully funds our business plan to cash flow positive," said Kip Underwood, Burcon's chief executive officer.
  • "In response to significant customer interest for our protein offerings, we are accelerating our commercial plans.
  • All securities issued in connection with the Offering are subject to a statutory hold period in Canada expiring four months and one day from the closing of the private placement.

ME Therapeutics Announces Closing of Non-Brokered Private Placement

Retrieved on: 
Wednesday, March 6, 2024

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, announces the closing of its previously announced non-brokered private placement financing (the "Offering") and has issued 1,555,000 units (each, a "Unit") at a price of $1.00 per Unit raising gross proceeds of $1,555,000.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - March 6, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, announces the closing of its previously announced non-brokered private placement financing (the "Offering") and has issued 1,555,000 units (each, a "Unit") at a price of $1.00 per Unit raising gross proceeds of $1,555,000.
  • Each Unit is comprised of one common share of the Company (each, a "Share") and one Share purchase warrant (each, a "Warrant").
  • All securities issued in connection with the Offering are subject to a statutory hold period expiring four months and one day after the date of the Closing.
  • No finder's fees were paid in connection with the Offering.

Cosa Resources Closes C$6.5 Million Private Placement

Retrieved on: 
Tuesday, March 5, 2024

Vancouver, British Columbia--(Newsfile Corp. - March 5, 2024) - Cosa Resources Corp. (TSXV: COSA) (OTCQB: COSAF) (FSE: SSKU) ("Cosa" or the "Company") is pleased to announce that it has closed the brokered private placement previously announced by the Company on February 12, 2024, as upsized on February 13, 2024, for aggregate gross proceeds of C$6,500,816 (the "Offering").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - March 5, 2024) - Cosa Resources Corp. (TSXV: COSA) (OTCQB: COSAF) (FSE: SSKU) ("Cosa" or the "Company") is pleased to announce that it has closed the brokered private placement previously announced by the Company on February 12, 2024, as upsized on February 13, 2024, for aggregate gross proceeds of C$6,500,816 (the "Offering").
  • The Offering was completed through a syndicate of underwriters, led by Haywood Securities Inc. and including PI Financial Corp. (collectively, the "Underwriters").
  • All Qualifying Expenditures will be renounced in favour of the subscribers of the Charity FT Units effective December 31, 2024.
  • Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Strathmore Announces Closing Private Placement for Gross Proceeds of $1,419,550

Retrieved on: 
Wednesday, February 28, 2024

Kelowna, British Columbia--(Newsfile Corp. - February 28, 2024) - Strathmore Plus Uranium Corporation (TSXV: SUU) (OTCQB: SUUFF) (or "the Company") is pleased to report that it has closed its previously announced non-brokered private placement for aggregate gross proceeds of $1,419,550 through the issuance of 2,839,100 units at a price of $0.50 per unit.

Key Points: 
  • Kelowna, British Columbia--(Newsfile Corp. - February 28, 2024) - Strathmore Plus Uranium Corporation (TSXV: SUU) (OTCQB: SUUFF) (or "the Company") is pleased to report that it has closed its previously announced non-brokered private placement for aggregate gross proceeds of $1,419,550 through the issuance of 2,839,100 units at a price of $0.50 per unit.
  • Each Unit consists of one common share of the Company and one-half common share purchase warrant (a "Warrant").
  • Each Full Warrant entitles the holder to purchase one common share of the Company at a price of $0.70 per share for a period of 24 months following the date of issuance.
  • Proceeds from the Offering will be used for working capital and further exploration of the Company's Wyoming properties, including drilling, soil sampling and geophysics.

ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update

Retrieved on: 
Tuesday, February 27, 2024

The Company confirms that the Offering Price was reserved confidentially on January 31, 2024 pursuant to section 6.2(4) of Policy 6 of the Canadian Securities Exchange (the "Exchange").

Key Points: 
  • The Company confirms that the Offering Price was reserved confidentially on January 31, 2024 pursuant to section 6.2(4) of Policy 6 of the Canadian Securities Exchange (the "Exchange").
  • Each Unit will be comprised of one common share of the Company (each, a "Share") and one Share purchase warrant (each, a "Warrant").
  • Completion of the Offering remains subject to certain conditions, including confirmation of no objection from the Exchange.
  • The Company continues to pursue research and development of its G-CSF antibody candidate, myeloid prodrug candidate and novel LNP formulation as previously disclosed in the Company's corporate update news release dated January 25, 2024.

Metabolica Health Completes Amalgamation with Big Fish and Announces Non-Brokered Private Placement

Retrieved on: 
Monday, February 26, 2024

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Metabolica Health Inc. ("Metabolica" or the "Company") a pioneering biotechnology firm at the forefront of diabetes and obesity treatment research, is pleased to announce the completion of its amalgamation (the "Amalgamation Agreement") with Big Fish Acquisition Corp. ("Big Fish"), effective on January 1, 2024, with the resulting amalgamated company, named Metabolica Health Inc. ("Metabolica Health"), continuing the business of Metabolica.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Metabolica Health Inc. ("Metabolica" or the "Company") a pioneering biotechnology firm at the forefront of diabetes and obesity treatment research, is pleased to announce the completion of its amalgamation (the "Amalgamation Agreement") with Big Fish Acquisition Corp. ("Big Fish"), effective on January 1, 2024, with the resulting amalgamated company, named Metabolica Health Inc. ("Metabolica Health"), continuing the business of Metabolica.
  • Pursuant to the terms of the Amalgamation Agreement dated October 30, 2023, Big Fish amalgamated with Metabolica to form Metabolica Health, and the issued shares of each of Metabolica and Big Fish were exchanged for shares of Metabolica Health or otherwise dealt with as follows: (a) each Class A Common share of Metabolica was exchanged for 22.213 common shares of Metabolica Health; and (b) each common share of Big Fish was exchanged for one-half of one common share of Metabolica Health.
  • Following the successful amalgamation transaction (the "Transaction"), Metabolica Health is pleased to announce that it is arranging a non-brokered private placement (the "Offering") of up to 2,500,000 Units, at a price of $0.40 per Unit, for gross proceeds of up to $1,000,000.
  • Furthermore, Metabolica Health is announcing the appointment of Mr. Scott Jardin, CPA, CGA, as the company's Chief Financial Officer.

Roscan Gold Announces Debt Settlement and Proposed Financing

Retrieved on: 
Wednesday, February 21, 2024

Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Roscan Gold Corporation (TSXV: ROS) (FSE: 2OJ) (OTCQB: RCGCF) ("Roscan" or the "Company") is pleased to announce that it has agreed to settle (the "Debt Settlement") an aggregate of USD$1,005,000 debt owed to an arm's length creditor through the issuance of a secured convertible promissory note (the "Note").

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Roscan Gold Corporation (TSXV: ROS) (FSE: 2OJ) (OTCQB: RCGCF) ("Roscan" or the "Company") is pleased to announce that it has agreed to settle (the "Debt Settlement") an aggregate of USD$1,005,000 debt owed to an arm's length creditor through the issuance of a secured convertible promissory note (the "Note").
  • The Note issued pursuant to the Debt Settlement shall be secured by way of a general security agreement providing security ranking subordinate to the other secured indebtedness of the Company, over all of the present and after-acquired property of the Company.
  • It is expected that insiders of the Company will participate in the Offering for CAD$400,000 principal amount of Convertible Notes.
  • All securities issued in connection with the Offering and the Debt Settlement will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.

Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million

Retrieved on: 
Monday, March 11, 2024

VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”) for total gross proceeds of approximately $30 million.

Key Points: 
  • NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES
    VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”) for total gross proceeds of approximately $30 million.
  • The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed.
  • Closing of the Offering will be subject to a number of customary conditions, including the entering into of the Underwriting Agreement and approval of the Toronto Stock Exchange.
  • The Offering will be made in Canada only by means of the base shelf prospectus and prospectus supplement.

Mirasol Resources Announces Private Placement Financing

Retrieved on: 
Friday, March 8, 2024

VANCOUVER, British Columbia, March 08, 2024 (GLOBE NEWSWIRE) -- Mirasol Resources Ltd. (TSX-V: MRZ) (OTCPK: MRZLF) (the “Company” or “Mirasol”) today announced it is arranging a non-brokered private placement financing (the “Offering”) of up to 5,000,000 Units (the “Units”) at a price of $0.60 per Unit for aggregate gross proceeds of $3.0 million.

Key Points: 
  • VANCOUVER, British Columbia, March 08, 2024 (GLOBE NEWSWIRE) -- Mirasol Resources Ltd. (TSX-V: MRZ) (OTCPK: MRZLF) (the “Company” or “Mirasol”) today announced it is arranging a non-brokered private placement financing (the “Offering”) of up to 5,000,000 Units (the “Units”) at a price of $0.60 per Unit for aggregate gross proceeds of $3.0 million.
  • The net proceeds of the Offering will be used to expand Mirasol’s successful exploration programs and for general corporate purposes.
  • This press release is not an offer of common shares for sale in the United States.
  • The Shares have not been and will not be registered under the U.S. Securities Act, or any state securities laws.

Landsea Homes Announces Closing of Secondary Common Stock Offering

Retrieved on: 
Friday, March 8, 2024

DALLAS, March 08, 2024 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”), a publicly traded residential homebuilder, announced today the closing of its previously announced underwritten secondary offering by its largest stockholder, Landsea Holdings Corporation (the “Selling Stockholder”), of 2,434,783 shares of the Company’s common stock, at a price of $11.60 per share (before underwriting discounts and commissions), and the full exercise by the underwriters of their option to purchase an additional 365,217 shares the Company’s common stock (the “Offering”).

Key Points: 
  • DALLAS, March 08, 2024 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”), a publicly traded residential homebuilder, announced today the closing of its previously announced underwritten secondary offering by its largest stockholder, Landsea Holdings Corporation (the “Selling Stockholder”), of 2,434,783 shares of the Company’s common stock, at a price of $11.60 per share (before underwriting discounts and commissions), and the full exercise by the underwriters of their option to purchase an additional 365,217 shares the Company’s common stock (the “Offering”).
  • B. Riley Securities and BofA Securities acted as joint bookrunning managers in the Offering.
  • The Company did not offer any shares of its common stock in the Offering and did not receive any of the proceeds from the sale of the shares offered by the Selling Stockholder.
  • “The closing of the Offering marks a significant milestone for our company,” said Landsea Homes Chief Executive Officer John Ho.